Assessment of Ventilation-Perfusion Abnormalities in Patients With Stable Smoking-Related Airways Disease
The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Imperial College London.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Imperial College London
Collaborator:
GlaxoSmithKline
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00180843
First received: September 13, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Subjects undergo history, examination, lung function assessment after informed consent has been obtained. All subjects will undergo ventilation-perfusion scans. If there first scan is normal they will undergo a second and final scan four weeks later. If abnormal they will undergo two further scans with either nebulized bronchodilator or nebulized saline prior to their second and third scans. Each time they will have repeat lung function tests prior to scanning. We will examine the regional changes in ventilation and perfusion and there relationship to lung function.
| Condition | Intervention |
|---|---|
|
Chronic Obstructive Pulmonary Disease |
Drug: salbutamol + ipratropium bromide nebules Procedure: ventilation-perfusion scan Procedure: lung function assessment |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Official Title: | Assessment of Ventilation-Perfusion Abnormalities in Patients With Smoking-Related Airways Disease in Stable Condition and the Effect of Bronchodilator Therapy |
Resource links provided by NLM:
Drug Information available for:
Albuterol
Ipratropium bromide
Levalbuterol
Levalbuterol hydrochloride
Albuterol sulfate
Levalbuterol tartrate
U.S. FDA Resources
Further study details as provided by Imperial College London:
Eligibility| Ages Eligible for Study: | 35 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- FEV1 < 70% predicted at baseline on spirometry
- significant smoking history or alpha 1 antitrypsin deficiency
- no evidence of current infection or restrictive lung disease
Exclusion Criteria:
- history of other significant respiratory disease
- significant respiratory infection within 6 weeks
- history of significant physical or mental illness rendering them unfit for the study in the opinion of the investigator
- taken part in any other research within the past 12 months, or received exposure to ionizing radiation
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00180843
Contacts
| Contact: Philip W Ind, MB Bchir MRCP | 02083831000 ext 33269 | pind@imperial.ac.uk |
| Contact: Jason e Burton, MB BS | 02083831000 ext 2350 | jburton@imperial.ac.uk |
Locations
| United Kingdom | |
| Imperial College Hammersmith Campus | Recruiting |
| London, United Kingdom, W12 0HS | |
| Contact: philip w ind, MB B Chir 02083831000 ext 33269 pind@imperial.ac.uk | |
| Principal Investigator: philip w ind, MBBChir MRCP | |
Sponsors and Collaborators
Imperial College London
GlaxoSmithKline
Investigators
| Principal Investigator: | Philip W Ind, MB BChir MRCP | Imperial College Hammersmith |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00180843 History of Changes |
| Other Study ID Numbers: | 04/6741 |
| Study First Received: | September 13, 2005 |
| Last Updated: | September 13, 2005 |
| Health Authority: | United Kingdom: Research Ethics Committee |
Additional relevant MeSH terms:
|
Congenital Abnormalities Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Respiratory Tract Diseases Albuterol Ipratropium Tocolytic Agents Reproductive Control Agents Physiological Effects of Drugs Pharmacologic Actions Therapeutic Uses |
Adrenergic beta-2 Receptor Agonists Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Cholinergic Antagonists Cholinergic Agents |
ClinicalTrials.gov processed this record on May 16, 2013